These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30790060)

  • 1. Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide.
    Araujo-Gutierrez R; Van Eps JL; Kirui D; Bryan NS; Kang Y; Fleming JB; Fernandez-Moure JS
    Biomed Microdevices; 2019 Feb; 21(1):23. PubMed ID: 30790060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
    Masetto F; Chegaev K; Gazzano E; Mullappilly N; Rolando B; Arpicco S; Fruttero R; Riganti C; Donadelli M
    Biochim Biophys Acta Mol Cell Res; 2020 Dec; 1867(12):118824. PubMed ID: 32828758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
    Duong HQ; Hong YB; Kim JS; Lee HS; Yi YW; Kim YJ; Wang A; Zhao W; Cho CH; Seong YS; Bae I
    J Cell Mol Med; 2013 Oct; 17(10):1261-70. PubMed ID: 23855452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulation of Gemcitabine on Porphyrin Aluminum Metal-Organic Framework by Mechano-Chemistry, Delayed Drug Release and Cytotoxicity to Pancreatic Cancer PANC-1 Cells.
    Umar S; Samokhvalov A
    Molecules; 2024 Jul; 29(13):. PubMed ID: 38999141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.
    Han H; Wang H; Chen Y; Li Z; Wang Y; Jin Q; Ji J
    Nanoscale; 2016 Jan; 8(1):283-91. PubMed ID: 26608864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
    Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
    Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines.
    Forika G; Kiss E; Petovari G; Danko T; Gellert AB; Krenacs T
    Pathol Oncol Res; 2021; 27():1610048. PubMed ID: 34955688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
    Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
    Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: biodistribution, pharmacokinetic and cytotoxicity study.
    Kush P; Kaur M; Sharma M; Madan J; Kumar P; Deep A; Kim KH
    Biomed Phys Eng Express; 2020 Feb; 6(2):025014. PubMed ID: 33438640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
    Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
    Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
    Yin N; Yu H; Zhang X; Lv X
    Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
    Donadelli M; Costanzo C; Beghelli S; Scupoli MT; Dandrea M; Bonora A; Piacentini P; Budillon A; Caraglia M; Scarpa A; Palmieri M
    Biochim Biophys Acta; 2007 Jul; 1773(7):1095-106. PubMed ID: 17555830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
    Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
    Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.
    Yu X; Song Y; Di Y; He H; Fu D; Jin C
    Sci Rep; 2016 Aug; 6():31539. PubMed ID: 27515795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.
    Yu X; Di Y; Xie C; Song Y; He H; Li H; Pu X; Lu W; Fu D; Jin C
    Int J Nanomedicine; 2015; 10():6825-34. PubMed ID: 26586944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
    Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.